Table 3. Lipid profile parameters at study baseline and 12-week after the intervention in patients who received either Co-Q10 or placebo.

Variables (mg/dL)		Co-Q10 (n = 39)	Placebo (n = 38)	MD (95% CI), p value
TC
	Before	171.97 ± 37.04	181.29 ± 34.42	9.32 (−6.93, 25.56), 0.257†
	After	169.67 ± 32.25	184.26 ± 41.62	6.95 (−5.03, 18.93), 0.251‡
	MD (95% CI)	−2.31 (−9.40, 4.78)	2.97 (−6.00, 11.94)
	p value*	0.514	0.506
LDL-c
	Before	100.33 ± 29.74	104.00 ± 29.32	3.67 (−9.74, 17.08), 0.588†
	After	93.62 ± 28.54	104.92 ± 33.53	9.38 (−1.35, 20.11), 0.086‡
	MD (95% CI)	−6.72 (−14.36, 0.92)	0.92 (−5.92, 7.77)
	p value*	0.083	0.787
HDL-c
	Before	50.77 ± 10.31	53.84 ± 11.27	3.07 (−1.83, 7.98), 0.216†
	After	55.67 ± 10.10	55.39 ± 11.35	−3.67 (−8.15, 0.82), 0.108‡
	MD (95% CI)	4.90 (1.16, 8.63)	1.55 (−1.50, 4.61)
	p value*	0.012	0.31
TG
	Before	104.15 ± 46.13	119.63 ± 51.17	15.48 (−6.63, 37.58), 0.167†
	After	101.36 ± 42.36	119.11 ± 52.13	11.17 (−7.12, 29.45), 0.227‡
	MD (95% CI)	−2.80 (−16.35, 10.76)	−0.53 (−13.18, 12.13)
	p value*	0.679	0.933

Data are expressed as mean ± standard deviation.

Co-Q10, Coenzyme Q10; MD, mean difference; CI, confidence interval; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.

^*The p value for comparing the changes of serum markers within groups based on the analysis of paired t-test.

^†Reported based on the analysis of independent sample t-test.

^‡Reported based on the analysis of covariance adjusted for baseline values and also, confounder variables (included age, years with migraine, changes in body mass index, body fat, physical activity, and energy).